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AML patients in CR1 who underwent Allo-SCT with RIC
regimen (Flu-Bu2-hATG) at UMass since 2010.
Results: 18 patients (12 males; 6 females) with a median age
of 67.5 (range 24-83) years were identiﬁed. Twelve (66%) had
prior MDS or poor prognostic cytogenetics. Induction
chemotherapy consisted of High dose Ara-C (HIDAC)/
Anthracycline (n¼17) and Decitabine (n¼1). Five patients
required reinduction to achieve a CR. Fourteen (78%)
received post CR therapy: HIDAC (n¼5), HIDAC/Hypo-
methylating agent (n¼3) and Hypomethylating agent alone
(n¼6). Seven (39%) patients had inadequate recovery of
counts (CRi). Median time from diagnosis to SCT was 130.5
(range 33 -384) days. Median Hematopoietic (H) SCT co-
morbidity index (CI) was 2.5 range (1- 9). SCT donors were
sibling (n¼2) and unrelated (n¼16). Seventeen (94%) pa-
tients were 8/8 HLA match and one (6%) was 7/8 HLA match.
Stem cell source was peripheral blood (n¼17) and G-CSF
primed marrow (n¼1). RIC dosing was Bu (3.2 mg/kg day x
2), Flu (30mg/m2 x 6) and hATG (20mg/kg x 3). Graft versus
Host Disease (GvHD) prophylaxis was calcineurin inhibitor/
mycophenolate-mofetil (MMF) (n¼16) and Sirolimus/MMF
(n¼2).
Median CD34 cells infusedwere 5 x 10e6/kg range (2.5-6).
All patients engrafted with a median time to neutrophil
engraftment of 15 days (range 10-22) and a median time to
platelet engraftment of 15 days (range 0-21). Non relapse
mortality at 100 days was 5.9%. Cumulative incidence of
grade 2-4 acute GvHD was 39%. For patients alive beyond 6
months the cumulative incidence of chronic gvhd was 64%.
Kaplan Meier estimate of 2 year overall (OS) and progression
free survival (PFS) was 80.5 % (95% CI 50.6-93.3%) and 69.9 %
(95% CI 36.7-88.0%) The median follow-up for the survivors
was 509 (59-1288) days. No patient with HSC-CI < 5 died
while all 3 patients with HSCT-CI > 6 expired (p < .001).
Presence of chronic gvhd was associated with a better PFS
(100% versus 32.1%) (p< .02) and a tendency for better OS
(100% versus 57.1%) (p¼ .06) indicating a preservation of
graft versus leukemia effect with this regimen.
Conclusion: Flu-Bu2-hATG RIC regimen has low early mor-
tality and improved PFS and OS for AML patients undergoing
Allo-SCT in CR1. The regimen should be evaluated in a pro-
spective clinical trial.223
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Chicago, ILThe alkylator Busulfan (Bu) is used in conditioning regimens
for acute leukemia prior to allogeneic stem cell transplant.
Multiple DNA repair mechanisms including mismatch repair
and base excision repair have been implicated in resistance
to Bu. The enzyme PARP is central to base excision repair. We
hypothesized that treatment of acute leukemia cell lines
with both ABT888 (Veliparib), an inhibitor of PARP 1 and 2,
and Buwould lead to synergistic cell kill and that this effect is
maximal in mismatch repair deﬁcient cells.
Two mismatch repair proﬁcient cell lines (K562 and HL60)
and 2 mismatch repair deﬁcient cell lines (NB4 and REH)
were treated with ABT888 alone, Bu alone or a combination
of both. In single drug experiments, doses of drug treatment
ranged from 0-400mcg/ml. In combination experiments a
ﬁxed dose of ABT888 of 1.25mcg/ml was utilized with Bu
doses varying from 0-200mcg/ml. This dose of ABT888 was
chosen as it approximated to patient blood levels in clinical
trials. After 24 hours of treatment, cells were washed and
resuspended in fresh medium. Proliferation of cells was
measured by standard 3H-thymidine uptake assay at 48
hours. Sigmoidal dose response curves and GI50 values were
then calculated. In addition, cells were tested for apoptosis
by ﬂow cytometry using activated caspase 3 and annexin/ PI
staining at 24 and 48 hours after treatment.
All 4 cell lines were found to be resistant to single agent
ABT888. Despite mismatch repair deﬁciency in REH cells,
therapeutic doses of ABT888 did not cause signiﬁcant de-
creases in proliferation. The effect of ABT888 was, as ex-
pected, much less evident in the mismatch repair proﬁcient
K562 cells. These cells were also relatively resistant to single
agent Bu in vitro. The combination of Bu and ABT888 was
synergistic in all cell lines with GI50 (micromoles/ml) for Bu
decreasing from 67.8 to 45.7 in K562, from 23.3 to 8.0 in
HL60, from 46.6 to 36.1 in NB4 and from 34.4 to 17.0 in REH
cells. The Combination Index was <1 in all cell lines indi-
cating synergy. Dose Reduction Index, indicating the factor
by which the dose of Bu can be decreased to achieve the
same treatment effect size, ranged from 1.45 to 3.1. The
synergistic effect was greatest in the mismatch repair deﬁ-
cient cell line REH (Combination Index 0.53, Dose Reduction
Index 3.1). As expected the synergistic effect observed did
not correlate with increased apoptotic death of leukemic
cells.
To our knowledge, this is the ﬁrst study to show synergy of a
clinically available PARP inhibitor with Bu. We believe this
data warrants further study with the potential clinical
application of increasing the anti-leukemic effect of stem cell
transplantation conditioned with Bu containing preparative
regimens.224
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Introduction: Overall survival (OS) after a standard allogeneic
hematopoietic cell transplantation (alloHCT) for refractory
